Tag: GlobeNewswire

SHENZHEN, China, Oct. 29, 2026 (GLOBE NEWSWIRE) — Nexpu Ltd. (Nasdaq: DPU) (“Nexpu” or the “Company”), formerly known as Top KingWin Ltd., today announced that selected third-party computing hardware and robotics products offered for resale by the Company, together with information about its customizable music creation platform (the “DPU Platform”), are listed on AlyXpress Orion. AlyXpress Orion is a third-party platform that is not owned or operated by the Company and also displays products from other companies. The listings provide product information and a channel for enquiries regarding hardware purchases, as well as a link to the DPU Platform. The Company does not manufacture or develop the featured hardware products.

Hardware Product Information and Enquiries

The Company’s listings on AlyXpress Orion present selected third-party hardware products offered for resale by Nexpu and information about the DPU Platform. The hardware listings serve as a product showcase and enquiry channel, rather than an online checkout platform. As of the date of this release, the Company has not generated revenue through these listings.

Prospective customers may use the email contact provided on AlyXpress Orion to submit hardware enquiries. Product specifications, quantities, availability, delivery schedules, pricing, warranty and after-sales terms must be confirmed separately with the Company before an order is placed. Any purchase is subject to mutually agreed written terms.

Access to the DPU Platform

The showcase also provides an entry point to DPU Platform, the customizable music creation platform offered through the Company’s subsidiary, Top Kingwin Technology Inc. Users may turn descriptions and lyrics into personalized music, manage their creations, and publish and share works within the platform.

Users access music services through the DPU Platform’s website, subject to applicable membership terms, usage allowances and licensing requirements.

Additional Online Listing Channel

The listings are intended to provide an additional channel for information and enquiries about the Company’s third-party hardware resale business and software business. The Company cannot assure that the listings will result in orders or revenue.

About Nexpu Ltd. (formerly known as Top KingWin Ltd.)

Nexpu Ltd. (formerly known as Top KingWin Ltd.) engages in the following business activities: (i) the resale of third-party devices that support data collection and analysis; (ii) the sale of robots; and (iii) the development and operation of software products and platforms.

Safe Harbor Statement

This announcement contains forward-looking statements made under the “safe harbor” provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These statements include expectations regarding product visibility, customer engagement and the commercial development of the Company’s third-party hardware resale and software businesses. These statements are based on management’s current expectations as of the date of this release and are subject to risks and uncertainties that could cause actual results to differ materially. These risks include whether online product listings and enquiries result in orders or revenue; dependence on third-party hardware suppliers for product availability, quality and warranty support; the Company’s ability to arrange fulfilment and after-sales services; the availability and performance of AlyXpress Orion, the DPU Platform and other third-party technology services; adoption of the DPU Platform; intellectual property, licensing and regulatory requirements; and other risks described in the Company’s filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement, except as required by law.

For further information, please contact:

Bonnie Zhang

Email: IR@tcjhgw.cn

Appointments strengthen scientific leadership and operational capabilities as Opus advances its pipeline of gene therapies for inherited retinal diseases

RESEARCH TRIANGLE PARK, N.C., Oct. 29, 2026 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced the appointments of Andrew Murphy, Ph.D., as Chief Scientific Officer and Jamie Lynne Hart, M.S., M.P.H., as Executive Director, Executive Operations. These appointments strengthen Opus Genetics’ scientific and operational capabilities as the Company advances its pipeline of gene therapies for inherited retinal diseases.

“As we continue to advance our clinical programs and expand our pipeline, strengthening our scientific leadership and operational capabilities is essential to supporting our next phase of growth,” said George Magrath, M.D., Chief Executive Officer, Opus Genetics. “Andy brings deep expertise in gene therapy research, AAV vector development and translational science that we expect will be invaluable as we advance our programs toward important clinical milestones. Jamie brings extensive experience in executive operations and organizational coordination, and as well as significant experience in the ophthalmology sector, which we believe will help us execute effectively across our growing organization. We are pleased to welcome both to the Opus Genetics team.”

Andrew Murphy, Ph.D., brings more than 18 years of biotechnology experience spanning gene therapy research, translational development and regulatory advancement. Prior to joining Opus Genetics, Dr. Murphy served as Senior Vice President of Research and Early Development at Kriya Therapeutics, where he led AAV vector design, research, genomics and data science activities, advancing gene therapy candidates across ophthalmology, metabolic, neurological and rare diseases.

Throughout his career, he has supported seven therapeutic programs through Phase 1 IND or CTA submissions, including five during his tenure at Kriya Therapeutics. Previously, Dr. Murphy founded Kitty Hawk Biosciences, a gene therapy consultancy focused on AAV vector characterization and potency assay development, and held scientific leadership positions at KBI Biopharma, Duke University Medical Center, ProteoVec and Liquidia Technologies. He holds a Ph.D. in Chemistry from Stanford University and a B.A. in Chemistry from Oberlin College.

Jamie Lynne Hart, M.S., M.P.H., brings more than 15 years of experience in biotechnology and ophthalmology, spanning executive operations, corporate development, medical affairs and clinical research. Prior to joining Opus Genetics, Ms. Hart served as Chief of Staff to the Chief Executive Officer at Apellis Pharmaceuticals (now Biogen), where she partnered with executive leadership and the Board of Directors to drive corporate strategy, portfolio prioritization and cross-functional execution across research, development and commercialization. Previously, she held several leadership positions at Ocular Therapeutix, including Director of Corporate Development and Alliance Management and Director of Medical Affairs, where she supported strategic partnerships, pipeline expansion and the company’s transition to commercialization. She was also on the medical affairs team at Shire Pharmaceuticals (now Takeda).

Earlier in her career, she was focused on clinical research in rare diseases and ophthalmic drug development. She has published extensively in uveitis, an orphan ophthalmic condition. Ms. Hart holds a Master of Science and a Master of Public Health from Tufts University School of Medicine, as well as undergraduate degrees from Boston University.

The appointments come as Opus Genetics continues to advance its ophthalmic gene therapy programs, including OPGx-BEST1 for BEST1-associated retinal disease, OPGx-LCA5 for Leber congenital amaurosis caused by mutations in the LCA5 gene and OPGx-RDH12 for RDH12-associated Leber congenital amaurosis. The Company remains focused on progressing its pipeline and developing innovative treatments for patients with inherited retinal diseases who have limited therapeutic options.

Forward-Looking Statements

This press release contains certain statements that are not statements of historical fact and are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “strive,” “will,” “would” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Such statements include, but are not limited to, statements related to the anticipated contributions of the Company’s newly appointed Chief Scientific Officer and Executive Director, Executive Operations and their potential to support the Company’s next phase of growth; the Company’s plans to advance its clinical programs and expand its pipeline; the Company’s expectations with respect to its growth and operational execution; and the Company’s expectations regarding its business prospects and results of operations. The forward-looking statements contained herein are subject to certain risks and uncertainties posed by many factors and events that could cause the Company’s actual business, prospects and results of operations to differ materially from those anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those described under the heading “Risk Factors” included in the Company’s most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in the Company’s other filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. Except as required by law, the Company undertakes no obligation to revise any forward-looking statements in order to reflect events or circumstances that might subsequently arise.

About Opus Genetics

Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with OPGx-RDH12 cleared to enter the clinic, and additional candidates targeting, MERTK, RHO, CNGB1 and NMNAT1. The Company is based in Research Triangle Park, N.C. For more information, visit www.opusgtx.com.

Contacts:

Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com

Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

Source: Opus Genetics, Inc.

Successfully Completed Consolidation of U.S. Brewing Footprint from 10 Facilities to Six

Identifying Further Opportunities to Reduce Complexity, Improve Brewery Utilization and Strengthen Margins

Transformation Initiatives Strengthen Operational Footprint Ahead of the Carlsberg U.S. Partnership Launching January 1, 2027; Targeting One Million Cases in First-Year Sales Through Tilray’s Existing Production and Distribution Infrastructure

Reaffirms Fiscal 2027 Adjusted EBITDA Guidance of $68 million to $75 million

NEW YORK and LONDON and LEAMINGTON, Ontario, Oct. 29, 2026 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company with leading positions across cannabis, beverage, hospitality and wellness, today announced additional initiatives across its U.S. beverage business, designed to reduce complexity and increase operational efficiency, targeting approximately $20 million in annualized cost savings by the end of fiscal 2028. Having now consolidated its U.S. brewing footprint from 10 facilities to six, Tilray is well-positioned to enter the next phase of transformation of its U.S. beverage business, pursuing additional opportunities across manufacturing, warehousing, procurement and logistics to lower production costs and increase utilization at its remaining breweries.

“We have taken meaningful steps to simplify our U.S. beverage operations, reducing our brewing footprint while optimizing our brand portfolio,” said Irwin D. Simon, Chairman and Chief Executive Officer of Tilray Brands. “Our next priority is to continue to reduce operational complexity through the consolidation of our distributor network, delivering improved margins and profit generation from our U.S. beverage operations. We are at the beginning of actioning these initiatives, and we anticipate they will flow through the broader business with the full impact anticipated in fiscal 2028. As such, we are reaffirming our fiscal 2027 Adjusted EBITDA guidance of $68 million to $75 million. With a more efficient cost structure and additional volume opportunities ahead, we expect these actions to drive margin expansion and stronger earnings across our U.S. beverage operations, while creating greater flexibility to reinvest in our brands, accelerate growth and deliver sustainable long-term shareholder value.”

Tilray has built a global beverage platform representing approximately $500 million in pro forma annual revenue, combining beloved consumer brands, state-of-the-art brewing infrastructure, experiential hospitality operations and extensive distribution capabilities. These transformational initiatives set the stage for the upcoming launch of Tilray’s U.S. partnership with Carlsberg on January 1, 2027, which represents an additional opportunity to leverage this simplified infrastructure and further optimize our distribution network.

Progress to Date: Simplifying Operations and Strengthening the Foundation for Growth

Since January 2025, Tilray has undertaken a series of initiatives to streamline its U.S. beverage operations, reduce operating costs and improve capital efficiency to combat inflationary pressures and higher input costs. These efforts have focused on three key areas: consolidating its brewing and production infrastructure, optimizing its national distribution network and rationalizing its brand portfolio.

Brewery Network and Asset Optimization

Tilray has consolidated its U.S. brewing footprint from 10 facilities to six, transferring production to its remaining breweries to improve capacity utilization. Over the last two years, these initiatives have included the closure of Hop Valley’s Eugene brewery, Redhook Brewlab and Revolver brewery, as well as the sale of the Atwater brand. During the second quarter of fiscal 2027, Tilray also transitioned Terrapin brewing production from Athens to other Tilray facilities while retaining the taproom, warehousing and repackaging operations at the Athens site.

National Distributor Consolidation

Since January 2025, Tilray has reduced its U.S. distributor network by approximately 9%, and the consolidation remains ongoing. Once completed, this initiative will enable the Company to concentrate its resources behind priority brands and core markets, strengthen distributor relationships and reduce the complexity and costs associated with managing a fragmented distribution network. We expect to substantially complete this plan through the end of fiscal 2028.

Strategic Portfolio Optimization

Tilray has rationalized its beverage portfolio to prioritize established regional brands, select national offerings and higher-potential growth categories, including non-alcoholic beverages and functional energy drinks. Since January 2025, the Company has reduced its SKU count by approximately 28%, eliminating duplicative, lower-margin, and slower-moving products. The reductions are intended to improve product mix, reduce operational complexity, and concentrate investment behind brands with stronger growth and profitability potential.

Looking Ahead: Additional Cost Savings and Future Growth Catalysts

Tilray has initiated an additional phase of transformation initiatives across its U.S. beverage business, designed to reduce complexity, counter cost headwinds and increase operational efficiency, targeting approximately $20 million in annualized cost savings by the end of fiscal 2028.

Tilray’s transformation plan includes the sale and monetization of several of its brewing and warehouse facilities that were made redundant in connection with the facility optimization plan designed to improve capacity utilization.

Tilray is reaffirming its fiscal 2027 Adjusted EBITDA guidance of $68 million to $75 million which already incorporates the anticipated benefits of cost reduction initiatives currently underway. As we advance additional operational efficiencies and cost savings initiatives, we expect these actions to create further opportunities for margin expansion and earnings growth beyond fiscal 2027. Given the anticipated timing of these initiatives, Tilray expects the majority of the incremental benefits to be realized by the end of fiscal 2028.

Carlsberg Partnership to Accelerate U.S. Growth

On January 1, 2027, Tilray will launch its exclusive U.S. brewing and commercial partnership with Carlsberg, bringing Carlsberg, Carlsberg Elephant, 1664 and 1664 Blanc to its national beverage platform. Under this agreement, Tilray will leverage its existing brewing infrastructure, sales organization and distribution network to produce and commercialize Carlsberg’s portfolio across the United States.

The partnership is targeting approximately one million cases in its first year, providing an opportunity to increase production volumes and improve capacity utilization across Tilray’s existing brewing network. By leveraging its established infrastructure, Tilray expects to support this additional volume without a proportionate increase in fixed operating costs, creating opportunities for improved operating leverage and profitability.

Positioned to Drive Sustainable Earnings Growth

With a more efficient operating structure, additional initiatives to reduce complexity are underway and new volume opportunities through partnerships, such as Carlsberg, Tilray is focused on translating the scale of its global beverage platform into improved financial performance. By leveraging its existing infrastructure to support incremental volume while maintaining disciplined cost management, the Company is positioned to improve operating leverage, expand margins, and strengthen cash generation.

About Tilray Brands

Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.

For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms.

Cautionary Statement Concerning Forward-Looking Statements

Certain statements in this press release constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “position,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication.

Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the Company’s ability to become a leading lifestyle consumer packaged goods company; the Company’s ability to become a leading beverage alcohol Company; the Company’s ability to achieve long term profitability; the Company’s ability to achieve operational scale, market share, distribution, profitability and revenue growth in particular business lines and markets; the Company’s ability to successfully achieve revenue growth, margin and profitability improvements, production and supply chain efficiencies, synergies and cost savings; the Company’s ability to achieve fiscal year 2027 financial guidance, including expected Adjusted EBITDA of $68 to $75 million and synergy optimizations; the anticipated launch, performance and renewal of the Carlsberg partnership; the expected benefits and timing of the Company’s distributor consolidation, portfolio optimization and brewery network optimization initiatives, including the substantial completion of restructuring initiatives by the end of fiscal 2027; the completion of planned sales and monetization of closed facilities; the Company’s expected revenue growth, sales volume, profitability, synergies and accretion related to any of its acquisitions; expected opportunities in the U.S., including upon U.S. federal cannabis legalization or rescheduling and the Company’s ability to leverage its platform in connection therewith; the Company’s ability to successfully leverage artificial intelligence strategies; the Company’s anticipated investments and acquisitions, including in organic and strategic growth, partnership efforts, product offerings and other initiatives; and the Company’s ability to commercialize new and innovative products.

Many factors could cause actual results, performance or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of the Company and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of the Company made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

For further information, please contact:

Media: news@tilray.com

Investors: investors@tilray.com

BEDFORD, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in November 2026.

Upcoming Investor Conference:

UBS Global Biopharma Conference 2026:
Date: Tuesday, November 17, 2026
Fireside Chat: 12:00 – 12:30 PM GMT
Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Location: London, UK

A live webcast of the fireside chat can be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcasts will be archived for at least 30 days following the presentation.

Upcoming Scientific Conferences:

The Empire Forum: November 5, 2026
New York, NY

• Presentation Title: Ocular Therapeutix, Redefining the Retina Experience
  Session: The Durability Race, Wet Age-Related Macular Degeneration
  Presentation Date/Time: Thursday, November 5, 2026, 2:51 – 2:58 PM ET
  Presenter: Jeffrey S. Heier, MD, Chief Scientific Officer

OSN New York & OSN New York Retina 2026: November 6-8, 2026
New York, NY

• Symposium: Redefining the Management of nAMD: The Impact of Durability and Sustained Disease Control
  Symposium Date/Time: Saturday, November 7, 2026, 5:00 – 6:00 PM EST
  Presenters: Mark R. Barakat, MD, FASRS; Andrew Moshfeghi, MD, MBA, FASRS; Dilsher S. Dhoot, MD, FASRS; Yasha S. Modi, MD, FASRS; Jeffrey S. Heier, MD, Chief Scientific Officer

Exact medical conference presentation times may be subject to change.

About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA^®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.

Follow the Company on its website, LinkedIn, or X.

DEXTENZA^® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com

Jet Excellence charter operator will use Gogo’s flexible financing solution to install high-speed, low-latency connectivity on its entire Citation X fleet

BROOMFIELD, Colo., Oct. 29, 2026 (GLOBE NEWSWIRE) — Gogo (NASDAQ: GOGO) today announced that Jet Excellence, a leading U.S.-based charter operator, will equip its entire fleet of Cessna Citation X aircraft with the Gogo Galileo HDX connectivity system. Jet Excellence is also taking advantage of Gogo’s flexible financing solution, helping the operator manage the cost of upgrading all of its Citation X fleet while accelerating access to the latest high-performance inflight connectivity technology.

The announcement follows receipt of a Federal Aviation Administration (FAA) Supplemental Type Certificate (STC) for the installation of Gogo Galileo HDX on the Citation X. Installations by Araina Aviation are beginning immediately.

Jet Excellence provides aircraft capacity to many of the business aviation industry’s leading fractional ownership, membership and charter providers. Equipping its entire Citation X fleet with Gogo Galileo will enable Jet Excellence to offer consistent and high-performance connectivity across more of its aircraft.

“Reliable inflight connectivity has become a crucial part of the service our customers expect us to provide,” says McQueen Campbell, CEO at Jet Excellence. “Gogo Galileo gives us the performance and global coverage needed to support passengers who want to remain productive and entertained throughout their flights. Gogo’s financing solution also gives us a practical way to introduce that capability across our fleet on an accelerated schedule.”

Gogo Galileo is powered by Eutelsat’s OneWeb enterprise-grade low-earth-orbit (LEO) satellite network, providing high-speed, low-latency connectivity around the world. Passengers and crew can simultaneously use multiple devices for video conferencing, streaming, email, communications and internet browsing. The Galileo HDX electronically steered antenna offers a compact, lightweight, aerodynamic and low-power solution capable of delivering reliable high speeds. Gogo Galileo is optimized for aircraft ranging from turboprops and light jets to larger business aircraft.

“Jet Excellence operates in an environment where aircraft availability, operating economics and a consistent passenger experience are all critical,” says Christopher Moore, Chief Executive Officer for Gogo. “Our role is not simply to provide connectivity, but to help customers choose, integrate and support the solution that’s right for their operation. By combining Gogo Galileo with flexible financing, we’re making it easier for operators to modernize their fleets and invest with confidence.”

Gogo’s flexible financing solution is designed to make advanced connectivity more accessible by allowing operators to pay for the equipment in installments over five years. As part of Gogo’s customer-first approach, customers also benefit from predictable pricing, 24/7/365 multilingual support, and a commitment to data privacy and cybersecurity. Built on a future-ready platform, Gogo Galileo enables operators to adapt as connectivity technologies and operational requirements continue to evolve.

Photo caption: Jet Excellence will equip its entire fleet of Cessna Citation X aircraft with Gogo Galileo HDX high-speed, low-latency connectivity.

About Gogo
Gogo has been the trusted connectivity infrastructure partner for business aviation and military/government for three decades. Rather than promoting a single network or technology, Gogo helps customers navigate an increasingly complex connectivity landscape by combining deep market knowledge, global aviation expertise and expert guidance to identify, integrate and support the connectivity solution best suited to their aircraft, mission and operational requirements.

Providing access to a complete network neutral connectivity ecosystem including onboard hardware, software, air-to-ground and multi-orbit, multi-band satellite connectivity, service plans, and 24/7/365 multilingual customer support, Gogo delivers customers the flexibility, choice and long-term partnership they need through a single trusted provider. Dedicated to its customer-first philosophy, the company combines long-standing customer relationships with a commitment to cybersecurity, data privacy, flexible financing, predictable long-term pricing, and future-proofed technology to help customers invest with confidence.

From light business aircraft to executive airliners and specialized government platforms, Gogo delivers secure, reliable connectivity that enables customers to fly, work and connect with confidence.

Media contacts – Gogo

Caroline Phaneuf – Arena Group         
caroline@arenagroupassociates.com                                
+1 514 778 5092        

Stacey Giglio                                                                       
sgiglio@gogoair.com                          
+1 321 361 6101

Investor contact – Gogo

Amy Greene
alocasciogreene@gogoair.com
+1 303 301 3313
                        

Cautionary Note Regarding Forward-Looking Statements

Certain disclosures in this press release and related comments by our management include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding our business outlook, industry, business strategy, plans, goals and expectations concerning our market position, international expansion, future technologies, future operations, margins, profitability, future efficiencies, capital expenditures, liquidity and capital resources and other financial and operating information. When used in this discussion, the words “anticipate,” “assume,” “believe,” “budget,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “future” and the negative of these or similar terms and phrases are intended to identify forward-looking statements in this press release. Forward-looking statements are based on our current expectations regarding future events, results or outcomes. These expectations may or may not be realized. Although we believe the expectations reflected in the forward-looking statements are reasonable, we can give you no assurance these expectations will prove to have been correct. Some of these expectations may be based upon assumptions, data or judgments that prove to be incorrect. Actual events, results and outcomes may differ materially from our expectations due to a variety of known and unknown risks, uncertainties and other factors. Although it is not possible to identify all of these risks and factors, they include, among others, the following: our ability to continue to generate revenue from the provision of our connectivity and other service offerings; our development and fixed-price contracts; our reliance on our key OEMs and dealers for equipment sales; our dependence on single-source, third party satellite network providers; the impact of competition; our ability to maintain high-quality customer support; our reliance on third parties for equipment components and services; our participation in U.S. government contracts; our participation in non-U.S. government contracts; the finite useful life of satellites; the impact of global supply chain and logistics issues, tariffs and inflationary trends; the continued expansion of our business outside of the United States; foreign currency risk; our ability to recruit, train and retain highly skilled employees, and the loss of any key personnel; the impact of pandemics or other outbreaks of contagious diseases, and the measures implemented to combat them; the impact of adverse economic conditions; our ability to fully utilize portions of our deferred tax assets; the impact of attention to climate change, conservation measures and other sustainability-related matters; our ability to evaluate or pursue strategic opportunities; our ability to integrate Satcom Direct’s business, and the potential failure to realize or delay in realizing all of the anticipated benefits of the acquisition; the changes in executive management that occurred as part of the Satcom Direct acquisition; our ability to develop and deploy Gogo 5G, Gogo Galileo or other next generation technologies; our ability to maintain our rights to use our licensed 4Mhz of ATG spectrum in the United States and obtain rights to additional spectrum if needed; the impact of service interruptions or delays, cyberattacks, technology failures, equipment damage or system disruptions or failures; the impact of assertions by third parties of infringement, misappropriation or other violations; our ability to innovate and provide products and services; our ability to protect our intellectual property rights; risks associated with the use of artificial intelligence in our products and services; the impact of our use of open-source software; the impact of equipment failure or material defects or errors in our software; our ability to comply with applicable foreign ownership limitations; the impact of government regulation of communication networks, and the internet; the ongoing partial government shutdown; our possession and use of personal information; risks associated with participation in the FCC Reimbursement Program; our ability to comply with anti-bribery, anti-corruption and anti-money laundering laws; the extent of expenses, liabilities or business disruptions resulting from litigation; the impact of global climate change and legal, regulatory or market responses to it; the impact of the distribution of income among various jurisdictions in which we operate as well as changes in tax law or regulation on our U.S. and non-U.S. tax liabilities; the impact of changes in laws and regulations on U.S. government contractors; the impact of our substantial indebtedness; our ability to obtain additional financing to refinance or repay our existing indebtedness the impact of restrictions and limitations in the agreements and instruments governing our debt; the impact of an increase in interest rates; the impact of a substantial portion of our indebtedness being secured by substantially all of our assets; the impact of a substantial change in rating assigned by a rating agency; the volatility of our stock price; our ability to fully utilize our tax losses; the dilutive impact of future stock issuances; the impact of our stockholder concentration; our ability to fulfill the obligations of being  a public company; the impact of an identified material weakness in our internal controls; the impact of certain provisions of our charter, bylaws, and Delaware law; and other factors listed under the caption “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2025 as filed with the Securities and Exchange Commission (“SEC”) on February 27, 2026 and in our subsequent quarterly reports on Form 10-Q as filed with the SEC.

Any one of these factors or a combination of these factors could materially affect our financial condition or future results of operations and could influence whether any forward-looking statements contained in this report ultimately prove to be accurate. Our forward-looking statements are not guarantees of future performance, and you should not place undue reliance on them. All forward-looking statements speak only as of the date made and we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fb47b9c0-e25f-44b5-aead-527ee569c670

• Q3’26 Total Net Revenue of $356 Million, Up 13% YoY
• Record Quarterly Total SUBLOCADE® Net Revenue of $267 Million in Q3’26, Up 22% YoY
• Record Quarterly Net Income of $137 Million and Record Non-GAAP Net Income of $161 Million in Q3’26
• Record Quarterly Adjusted EBITDA of $211 Million in Q3’26, Up 76% YoY
• Net Income Margin of 39%, up 2,500 basis points YoY, Adjusted EBITDA Margin of 59%, Up 2,100 Basis Points YoY
• On Track to Close Merger with Supernus on November 2nd

RICHMOND, Va., Oct. 29, 2026 (GLOBE NEWSWIRE) — Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today reported its financial results for the third quarter ended September 30, 2026.

“In the third quarter, we delivered record SUBLOCADE net revenue and record adjusted EBITDA, reflecting the strength of our business and the disciplined execution of the Indivior Action Agenda,” said Joe Ciaffoni, Chief Executive Officer. “Upon the imminent closing of our merger with Supernus, we will have successfully completed all three phases of the Indivior Action Agenda. I want to thank the Indivior team for their commitment and hard work that generated these results and made the transaction with Supernus possible. I am confident in Supernus’ future and its ability to build on this strong foundation for people living with central nervous system diseases and to create long-term value for shareholders.”

“We achieved record financial performance in the third quarter, including SUBLOCADE net revenue growth of 22% year-over-year and adjusted EBITDA margin of 59%, up 2,100 basis points year-over-year,” said Ryan Preblick, Chief Financial Officer. “Our strong results and the execution of our Indivior Action Agenda puts us on track to achieve our previously communicated 2026 financial guidance, excluding the impact of our pending acquisition. Strong cash generation brought cash and investments to $332 million at quarter end, adding to the financial strength we will bring to our merger with Supernus.”

Q3 2026 Business Highlights:

• As of September 30, 2026, over 583,000 patients in the U.S. have been prescribed SUBLOCADE since launch.
• Grew total SUBLOCADE net revenue 22% year-over-year to $267 million. U.S. SUBLOCADE net revenue increased 24% year-over-year to $252 million versus the prior year, primarily driven by 17% dispense unit volume growth. Net revenue also benefited from more favorable price/mix and gross-to-net adjustments.
• In August 2026, Indivior and Supernus Pharmaceuticals, Inc. (“Supernus”) announced a definitive agreement to combine in an all-stock merger of equals transaction to create a leading, diversified, scaled, CNS-focused biopharmaceutical company.
• In September 2026, Indivior announced that its Board of Directors declared a special cash dividend contingent upon closing of the pending merger transaction with Supernus.
• In October 2026, Indivior shareholders approved the proposed merger with Supernus. The merger is expected to close on November 2, 2026, at which time the combined company will operate as Supernus, Inc. and will trade on the Nasdaq Global Select Market under the ticker symbol “SUPN” beginning November 3, 2026.

Full-Year 2026 Financial Guidance:

Prior to the closing of the merger, Indivior is on track to achieve its previously communicated full year 2026 guidance as a standalone organization. That guidance assumed no material change in exchange rates for key currencies compared with 2025 average rates, notably USD/GBP and USD/EUR. Assuming the merger is completed November 2, 2026, we will operate as a combined company and the guidance will no longer apply.

	FY 2026 Guidance
Net Revenue	$1,295 million to $1,365 million
Total SUBLOCADE Net Revenue	$1,010 million to $1,050 million
Non-GAAP Operating Expenses*	$430 million to $450 million
Adjusted EBITDA*	$700 million to $740 million

*We did not provide the forward-looking U.S. GAAP equivalents for certain forward-looking non-U.S. GAAP metrics as a result of the uncertainty and potential variability of reconciling items. Instead, the Company has relied upon the exception in Item 10(e)(1)(i)(B) of Regulation S-K to exclude such reconciliations, as the reconciliations of these non-U.S. GAAP guidance metrics to their corresponding U.S. GAAP equivalents are not available without unreasonable effort.

Financial Results for Quarter Ended September 30, 2026:

• Total net revenue was $356 million for the quarter ended September 30, 2026 (the 2026 quarter), compared to $314 million for the quarter ended September 30, 2025 (the 2025 quarter), representing a 13% increase year-over-year.
• Total SUBLOCADE net revenue was $267 million for the 2026 quarter, compared to $219 million for the 2025 quarter, representing a 22% increase year-over-year.
• GAAP operating expenses were $125 million for the 2026 quarter, compared to $187 million for the 2025 quarter, representing a 33% decrease year-over-year. Non-GAAP operating expenses, which exclude stock-based compensation expense and other adjustments, were $103 million for the 2026 quarter, compared to $145 million for the 2025 quarter, representing a 29% decrease year-over-year.
• GAAP net income for the 2026 quarter was $137 million ($1.12 diluted earnings per share), compared to GAAP net income for the 2025 quarter of $42 million ($0.33 diluted earnings per share). Non-GAAP net income for the 2026 quarter was $161 million ($1.32 diluted earnings per share), compared to non-GAAP net income for the 2025 quarter of $93 million ($0.72 diluted earnings per share).
• Adjusted EBITDA for the 2026 quarter was $211 million, compared to $120 million for the 2025 quarter, representing a 76% increase year-over-year.
• The Company ended the 2026 quarter with cash and investments of $332 million.

Financial Results for Nine Months Ended September 30, 2026:

• Total net revenue was $1,016 million for the nine months ended September 30, 2026 (the 2026 period), compared to $881 million for the nine months ended September 30, 2025 (the 2025 period), representing a 15% increase year-over-year.
• Total SUBLOCADE net revenue was $753 million for the 2026 period, compared to $604 million for the 2025 period, representing a 25% increase year-over-year.
• GAAP operating expenses were $398 million for the 2026 period, compared to $521 million for the 2025 period, representing a 24% decrease year-over-year. Non-GAAP operating expenses, which exclude stock-based compensation expense and other adjustments, were $331 million for the 2026 period, compared to $459 million for the 2025 period, representing a 28% decrease year-over-year.
• GAAP net income for the 2026 period was $348 million ($2.78 diluted earnings per share), compared to GAAP net income for the 2025 period of $108 million ($0.85 diluted earnings per share). Non-GAAP net income for the 2026 period was $427 million ($3.41 diluted earnings per share), compared to non-GAAP net income for the 2025 period of $213 million ($1.68 diluted earnings per share).
• Adjusted EBITDA for the 2026 period was $562 million, compared to $286 million for the 2025 period, representing a 97% increase year-over-year.

About Indivior

As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine — developing treatments that help people move toward long-term recovery with independence and dignity. Building on this heritage, we are ushering in a new era, renewing our commitment to individuals living with OUD and carrying forward what matters most: compassion, integrity, and science. Together – with science, people living with OUD, public health champions, and communities, we are powering recovery and renewing hope. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/Indivior.

Columns and rows within financial tables may not foot due to rounding. Percentages and per share data in the financial tables have been calculated using actual, non-rounded figures.

Non-GAAP Financial Measures:

Non-GAAP financial measures adjust for non-recurring items and other items representing expenses or income that we believe do not reflect the Company’s ongoing operations or the adjustment of which may help with the comparison to prior periods. The Company believes its non-GAAP financial measures may be useful to investors to understand the Company’s performance. In addition, the Company uses “Adjusted EBITDA” in its annual incentive plan in which all executive officers participate.

Important Cautionary Note Regarding Forward-Looking Statements:

This announcement contains certain statements that are forward-looking statements. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements include, among other things, express and implied statements regarding: our 2026 financial guidance including with respect to net revenue, total SUBLOCADE net revenue, non-GAAP operating expenses, and adjusted EBITDA; the expected completion and timing of the closing of our previously announced merger with Supernus, including the payment and timing of the special cash dividend, the expected operation, performance, and prospects of the combined company; potential expense reductions; expected acceleration in SUBLOCADE net revenue and dispense unit growth; expected growth in adjusted EBITDA, cash flow, and our bottom line, and expected acceleration of such growth; expected creation of shareholder value; and other statements containing the words “believe,” “anticipate,” “plan,” “expect,” “intend,” “estimate,” “forecast,” “strategy,” “target,” “guidance,” “outlook,” “potential,” “project,” “priority,” “may,” “will,” “should,” “would,” “could,” “can,” the negatives thereof, and variations thereon and similar expressions. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future.

Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and only express management’s beliefs regarding future results or events which, by their nature, are inherently uncertain and outside of management’s control or ability to predict. Actual results may differ materially from those expressed or implied in these forward-looking statements due to a number of factors, including but not limited to: market disruptions or unanticipated delays; lower than expected future sales of our products; greater than expected impacts from competition; and unanticipated costs including the effects of potential tariffs and potential retaliatory tariffs; the effect of additional indebtedness incurred to fund the special cash dividend; potential business disruption and diversion of management attention; difficulties integrating the businesses; and potential failure to realize anticipated benefits and synergies. For additional information about some of the risks and important factors that could affect our future results and financial condition, see “Important Cautionary Note Regarding Forward-looking Statements” and “Risk Factors” in Indivior’s Annual Report on Form 10-K filed February 26, 2026, Indivior’s quarterly reports on Form 10-Q for the quarters ended March 31, June 30, and September 30, 2026, the definitive joint proxy statement/prospectus filed September 11, 2026, and our other filings with the U.S. Securities and Exchange Commission.

We have based the forward-looking statements in this release on our current expectations and beliefs concerning future events. Forward-looking statements contained in this release speak only as of the day they are made and, except as required by law, we undertake no obligation to update or revise any forward-looking statement, whether due to new information, or to reflect events or developments that occur after the date the statement was made.

Important Additional Information and Where to Find It
In connection with the proposed merger, Indivior filed a registration statement on Form S-4 with the SEC, which was declared effective on September 11, 2026 and includes a definitive joint proxy statement/prospectus. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT, DEFINITIVE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY BEFORE MAKING ANY VOTING OR INVESTMENT DECISION. Free copies of these documents and other documents filed by Indivior with the SEC may be obtained at the SEC’s website at www.sec.gov. Copies of Indivior’s filings may also be obtained free of charge on Indivior’s website at www.indivior.com, and copies of Supernus’s filings may be obtained free of charge on Supernus’s website at www.supernus.com.

No Offer or Solicitation
This announcement is not a solicitation of a proxy, consent or authorization in respect of any securities or in respect of the proposed merger, and it is not an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

For Further Information:

Investors	Jason Thompson	VP, Investor Relations	+1 804 402 7123 jason.thompson@indivior.com
Media	Cassie France-Kelly	VP, Communications	+1 804 594 0836 Indiviormediacontacts@indivior.com

Indivior Pharmaceuticals, Inc.
(Amounts in millions, except per share data and percentages)
(Unaudited)

Condensed consolidated statements of operations

	Three Months Ended September 30,						Nine Months Ended September 30,
		2026			2025			2026			2025
Net revenue	$	356		$	314		$	1,016		$	881
Cost of sales		51			83			140			179
Gross profit		305			230			875			702
Selling, general and administrative		119			154			364			445
Research and development		5			33			33			76
Total operating expenses		125			187			398			521
Operating income		180			43			477			181
Interest (income)		(4	)		(6	)		(9	)		(16	)
Interest expense		2			12			10			39
Loss on debt extinguishment		—			—			18			—
Income before income taxes		182			37			457			158
Income tax expense (benefit)		45			(5	)		109			50
Net income	$	137		$	42		$	348		$	108
Earnings per share
Basic	$	1.16		$	0.34		$	2.89		$	0.87
Diluted	$	1.12		$	0.33		$	2.78		$	0.85

Indivior Pharmaceuticals, Inc.
(Amounts in millions, except per share data and percentages)
(Unaudited)

Condensed consolidated balance sheets

	September 30, 2026			December 31, 2025
Assets
Current assets
Cash and cash equivalents	$	305		$	195
Accounts receivable, net of allowances of $3 (2026) and $4 (2025)		273			253
Inventories		149			153
Prepaid expenses		21			34
Current tax receivable		13			2
Other current assets		40			16
Total current assets		800			652
Long-term investments		27			28
Property, plant and equipment, net		175			144
Operating lease right of use assets, net		12			26
Goodwill and other intangible assets, net		2			2
Deferred tax assets		288			323
Other noncurrent assets		27			27
Total assets	$	1,332		$	1,201
Liabilities and stockholders’ deficit
Current liabilities
Accrued rebates and product returns	$	548		$	582
Accounts payable and accrued expenses		181			250
Accrued litigation settlement expenses, current		14			42
Current portion of long-term debt		488			29
Operating lease liabilities, current		7			10
Income taxes payable		63			2
Total current liabilities		1,301			914
Long-term debt, less current portion		—			290
Accrued litigation settlement expenses, noncurrent		42			52
Operating lease liabilities, noncurrent		6			22
Other noncurrent liabilities		42			21
Total liabilities		1,392			1,300
Stockholders’ deficit
Common stock, par value $0.001 per share (2026) and $0.50 per share (2025). Issued shares: 118 (2026) and 125 (2025)		—			62
Additional paid-in capital		163			112
Accumulated other comprehensive loss		(26	)		(30	)
Accumulated deficit		(197	)		(243	)
Total stockholders’ deficit		(60	)		(98	)
Total liabilities and stockholders’ deficit	$	1,332		$	1,201

Indivior Pharmaceuticals, Inc.
(Amounts in millions, except per share data and percentages)
(Unaudited)

Condensed consolidated statements of cash flows

	Nine Months Ended September 30,
		2026			2025
Cash flows from operating activities:
Net income	$	348		$	108
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization		5			8
Amortization of right-of-use assets		4			7
Stock-based compensation expense		28			21
Impairment of tangible and intangible assets		8			16
Loss on debt extinguishment		18			—
Unrealized loss on equity investments		—			1
Deferred income taxes		35			(8	)
Impact from foreign exchange movements		4			(2	)
Amortization of debt issuance costs		1			—
Other adjustments, net		—			2
Change in operating assets and liabilities		(135	)		42
Net cash provided by operating activities		317			194
Cash flows from investing activities:
Purchases of property and equipment		(41	)		(42	)
Purchases of in-process research and development and intangible assets		—			(1	)
Purchases of investments in debt securities		(12	)		(14	)
Sales and maturities of debt securities		13			14
Net cash used in investing activities		(41	)		(42	)
Cash flows from financing activities:
Proceeds from the issuance of common stock		—			2
Cash paid for repurchases of common stock		(302	)		(11	)
Proceeds from debt, net		489			—
Repayments of debt		(333	)		(12	)
Transaction costs related to debt refinancing		(5	)		—
Settlement of equity awards		(21	)		(3	)
Other		6			—
Net cash used in financing activities		(166	)		(25	)
Net increase in cash and cash equivalents		110			128
Exchange differences		—			(1	)
Cash and cash equivalents at beginning of period		195			319
Cash and cash equivalents at end of period	$	305		$	445

Indivior Pharmaceuticals, Inc.
(Amounts in millions, except per share data and percentages)
(Unaudited)

Selected revenue information

	Three Months Ended September 30,				Nine Months Ended September 30,
		2026		2025		2026		2025
US:
SUBLOCADE*	$	252	$	203	$	707	$	561
Sublingual & other		53		51		160		157
OPVEE1		—		8		—		8
PERSERIS2		2		6		12		19
Total U.S.		307		267		880		745
Rest of World		48		47		136		137
Net revenue	$	356	$	314	$	1,016	$	881
*Total SUBLOCADE net revenue	$	267	$	219	$	753	$	604

¹Discontinued sales and marketing support for OPVEE® during Q3 2025.

²Marketing and promotion activities for PERSERIS were discontinued in 2024.

Reconciliation of GAAP to non-GAAP financial information

	Three Months Ended September 30,				Nine Months Ended September 30,
		2026		2025		2026		2025
GAAP operating expenses	$	125	$	187	$	398	$	521
Stock-based compensation		8		6		28		21
Corporate initiative transition1		14		35		38		41
Litigation settlement expense		—		—		—		1
Less: Adjustments in operating expenses		22		42		67		62
Non-GAAP operating expenses	$	103	$	145	$	331	$	459

¹Includes severance, consulting, impairment, and costs related to planned facility closures.

Non-GAAP diluted earnings per share
Management believes that non-GAAP diluted earnings per share, which excludes the impact of certain non-recurring items and other adjustments, net of applicable tax effects, may provide useful information to shareholders regarding underlying trends in earnings per share. A reconciliation of GAAP net income to non-GAAP net income, as well as the weighted average shares used in computing non-GAAP diluted earnings per share, is included in the table below.

	Three Months Ended September 30,						Nine Months Ended September 30,
		2026			2025			2026			2025
GAAP net income	$	137		$	42		$	348		$	108
Adjustments in cost of sales1		8			33			13			34
Adjustments in operating expenses		22			42			67			62
Adjustments in interest expense		—			—			—			4
Loss on debt extinguishment		—			—			18			—
Adjustments in tax expenses		(6	)		(24	)		(19	)		5
Non-GAAP net income	$	161		$	93		$	427		$	213
Shares used in computing diluted non-GAAP earnings per share		122			129			125			127
Non-GAAP diluted earnings per share	$	1.32		$	0.72		$	3.41		$	1.68

¹Includes manufacturing transition and other costs

Indivior Pharmaceuticals, Inc.
(Amounts in millions, except per share data and percentages)
(Unaudited)

Adjusted EBITDA
Adjusted EBITDA is a non-GAAP financial measure that represents GAAP net income adjusted to exclude interest expense, interest income, income tax expense or benefit, depreciation and amortization, stock-based compensation, and other adjustments reflecting changes in our business that do not represent ongoing operations. Adjusted EBITDA margin is Adjusted EBITDA divided by Total net revenue. Adjusted EBITDA, as used by us, may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.

	Three Months Ended September 30,						Nine Months Ended September 30,
		2026			2025			2026			2025
Net income	$	137		$	42		$	348		$	108
Interest (income)		(4	)		(6	)		(9	)		(16	)
Interest expense		2			12			10			39
Income tax expense (benefit)		45			(5	)		109			50
Depreciation and amortization		1			2			5			8
Stock-based compensation		8			6			28			21
Corporate initiative transition		20			35			45			41
Manufacturing transition		2			2			6			4
Discontinuation of OPVEE sales and marketing		—			30			—			30
Loss on debt extinguishment		—			—			18			—
Litigation settlement expense		—			—			—			1
Adjusted EBITDA	$	211		$	120		$	562		$	286

CICERO, Ill., Oct. 29, 2026 (GLOBE NEWSWIRE) — Broadwind (Nasdaq: BWEN, or the “Company”), a diversified precision manufacturer of specialized components and solutions serving global markets, today announced that it will issue third quarter 2026 results before the market opens on Thursday, November 12, 2026. A conference call will be held that same day at 11:00 a.m. ET to review the Company’s financial results, discuss recent events and conduct a question-and-answer session.

A webcast of the conference call and accompanying presentation materials will be available in the Investor Relations section of the Company’s corporate website at https://investors.bwen.com/investors. To listen to a live broadcast, go to the site at least 15 minutes prior to the scheduled start time in order to register, download, and install any necessary audio software.

To participate in the live teleconference:

Live Teleconference:	877-407-9716

To listen to a replay of the teleconference, which will be available through Thursday, November 19, 2026:

Teleconference Replay:	844-512-2921
Conference ID:	13762996

ABOUT BROADWIND 

Broadwind (Nasdaq: BWEN) is a precision manufacturer of structures, equipment and components for power generation, critical infrastructure, and other specialized applications. With facilities throughout the U.S., our talented team is committed to helping customers maximize performance of their investments—quicker, easier and smarter. Find out more at www.bwen.com

CONTACT: IR CONTACT

Noel Ryan, IRC or Brian Hawthorne
BWEN@val-adv.com

Pennsylvania credit union expands its digital banking experience with a secure, parent-controlled financial solution for families

BLUE BELL, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) — Rego Payment Architectures, Inc. (“REGO”) (OTCQB: RPMT), the leading white-label family financial lifecycle platform for financial institutions, today announced that Service 1st Federal Credit Union has launched Family Wallet, a youth banking experience powered by REGO and integrated within Service 1st’s digital banking experience. Service 1st has branded the experience designed specifically for kids as splashup!

Family Wallet gives parents a secure, supervised way to help their children build practical money skills, while splashup! gives kids an engaging way to earn, save, spend, and achieve goals. Parents maintain the visibility and control they need, and children gain real life experiences managing money. The integrated experience allows Service 1st to introduce younger members to digital banking within the same trusted relationship their families already have with the credit union.

“Financial empowerment has always been central to how Service 1st serves our members and communities,” said Christopher Court, Chief Strategy & Innovation Officer of Service 1st Federal Credit Union. “Family Wallet gives parents a practical way to teach healthy financial habits through real-life experience, with the oversight and safeguards families expect. By bringing this experience into our digital banking platform, we can support our members and their children through another important stage of their financial lives.”

Service 1st’s launch builds on a long-standing commitment to financial education. In 2025, the credit union held 18 high school financial reality fairs, including an event that engaged 1,890 students in hands-on learning focused on real-world financial decisions. Family Wallet extends that educational mission into members’ everyday digital banking experience.

“Service 1st understood that youth banking can deepen a financial institution’s relationship with the entire family while giving parents better tools to prepare their children for financial independence,” said Peter S. Pelullo, Chief Executive Officer of REGO. “Family Wallet gives banks and credit unions a differentiated, privacy-first family banking experience that can strengthen relationships across generations.”

REGO’s platform is designed from the ground up to protect children’s data and is certified to exceed the child data privacy requirements of the federal Children’s Online Privacy Protection Act, or COPPA. Financial institutions can deploy the platform under their own brand while maintaining the trusted relationship with their customers or members.

For more information about Service 1st Federal Credit Union, visit service1.org. For more information about REGO, visit regopayments.com.

About Service 1st Federal Credit Union

Service 1st Federal Credit Union is a full-service financial institution with total assets exceeding $850 million. We put the financial goals of our 53,000+ members at the heart of everything we do. Whether in one of our branches located in Bloomsburg, Danville, Elysburg, Lewisburg, Loyalsock, Mifflinburg, Montandon, Muncy, Shamokin Dam, Sunbury and Wilkes-Barre, or out and about in the community, our credit union team shares our core values that ensure our focus is always to strengthen the financial lives of our members and our community. After celebrating our 50th anniversary in 2025, we look forward to continuing this tradition for years to come. Member deposits are federally insured by the NCUA. For more information, visit service1.org.

About REGO

Rego Payment Architectures, Inc. (“REGO”) is a family digital wallet platform that empowers financial institutions to let their customers’ or members’ children spend, save, donate and invest in a safe, parent-controlled environment. Founded in 2008, REGO is the only family digital wallet platform to be certified COPPA (Children’s Online Privacy Protection Act) and third-party GDPR (General Data Protection Regulation) compliant. REGO has also been awarded multiple patents related to the safety of parent and child data, including age verification of users. Built from the ground up to protect the privacy of children’s data, REGO offers financial literacy tools for parents to teach their kids to be smarter shoppers, savers, givers and investors. Financial institutions of all sizes can offer a family digital wallet product through REGO as a white-labeled stand-alone application or fully integrated into their existing app. For more information, visit regopayments.com.

REGO Safe Harbor Statement

The information in this press release may contain forward-looking statements on REGO’s current expectations and projections about future events. These forward-looking statements are not guarantees and are subject to known and unknown risks, uncertainties, and assumptions about REGO that may cause the actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by such forward-looking statements. Important factors that could cause actual results to differ materially from REGO’s expectations include, but are not limited to: REGO’s ability to raise additional capital, the absence of any material operational history or revenue, REGO’s ability to attract and retain qualified personnel, the ability to develop and introduce a new service and products to the market in a timely manner, market acceptance of REGO’s services and products, REGO’s limited experience in the industry, the ability to successfully develop licensing programs and generate business, rapid technological change in relevant markets, unexpected network interruptions or security breaches, changes in demand for current and future intellectual property rights, legislative, regulatory and competitive developments, intense competition with larger companies, general economic conditions, and other risks as described by REGO in Item 1.A “Risk Factors” in REGO’s most recent Form 10-K; other risks to which REGO is subject; and other factors beyond REGO’s control.

All subsequent written and oral forward-looking statements attributable to REGO, or persons acting on REGO’s behalf, are expressly qualified in their entirety by the foregoing. REGO has no obligation to and does not undertake to update, revise, or correct any of these forward-looking statements after the date of this report.

Media Contact

Pawan Murthy
Chief Marketing Officer
Rego Payment Architectures, Inc.
pawan@regopayments.com

• Diranersen late-breaking symposium will feature 96-week long-term extension data and additional 76-week biomarker and clinical data from the Phase 2 CELIA study in early Alzheimer’s disease
• Lecanemab presentations will highlight new long-term and real-world evidence, including initial five-year Clarity AD open-label extension data and three-year LEADER data, with new analyses exploring maintenance treatment and at-home subcutaneous administration
• Presentations across Biogen’s Alzheimer’s disease portfolio reflect its continued commitment to advancing innovation in Alzheimer’s disease, from long-term treatment outcomes and real-world evidence to investigational approaches targeting core disease pathologies, including amyloid and tau

CAMBRIDGE, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced it will present new data across its Alzheimer’s disease portfolio at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, taking place November 16–19, 2026, at the Boston Marriott Copley Place in Boston, Massachusetts. Presentations will include expanded data from the Phase 2 CELIA study evaluating diranersen, an investigational tau-targeting antisense oligonucleotide (ASO), and new analyses from studies of lecanemab (brand name: LEQEMBI^®).

“Biogen has a long-standing commitment to advancing innovation in Alzheimer’s disease, from generating evidence that informs clinical practice to pursuing novel approaches that target core disease pathologies,” said Priya Singhal, M.D., M.P.H., Executive Vice President and Head of Development at Biogen. “At CTAD, we look forward to sharing important updates across our portfolio, including additional long-term and real-world evidence for LEQEMBI and new data from the Phase 2 CELIA study evaluating diranersen.”

Featured Scientific Sessions and Presentations

Diranersen
Diranersen is an investigational ASO designed to target MAPT mRNA and reduce the production of all tau isoforms, lowering both intracellular and extracellular tau protein. At CTAD, Biogen will present clinical, biomarker and safety data that build on results previously reported in July 2026 and further characterize the clinical, biomarker and safety profile of diranersen in the Phase 2 CELIA study in early Alzheimer’s disease.

• Late Breaking Symposium: Additional Biomarker and Clinical Findings from the Phase 2 CELIA Study of Diranersen in Early Alzheimer’s Disease: Late Breaking Symposium 1, Tuesday, November 17, 4:45–5:25 PM EST
  This symposium will feature three analyses from CELIA, including 96-week long-term extension efficacy and safety data, additional 76-week tau biomarker and amyloid PET data, and 76-week item analyses and select subgroup efficacy data. These data build on previously reported CELIA results and further characterize the clinical, biomarker and safety profile of diranersen in early Alzheimer’s disease.

Lecanemab
Featured lecanemab sessions at CTAD will highlight continued real-world evidence generation and long-term outcomes data related to the treatment of early Alzheimer’s disease.

• Symposium 5: Featured Research Session: Lecanemab Three Years Post-Approval: A Comprehensive Multicenter, Real-World, Retrospective Study (LEADER) in Diverse U.S. Clinical Settings
  Wednesday, November 18, 11:00–11:40 AM EST
  This session will feature new real-world evidence from the LEADER study, including findings on lecanemab utilization and outcomes from treatment initiation through maintenance therapy, sex-based outcomes, and experience with at-home subcutaneous lecanemab administration across diverse U.S. clinical settings.
• Oral Communication: Long-Term Outcomes with Lecanemab in Early Alzheimer’s Disease: Initial Findings Through 60-Months of Clarity AD Open-Label Extension
  Monday, November 16, 6:00 PM EST
  This oral presentation will report initial findings through five years of the Clarity AD open-label extension, including long-term clinical outcomes, disease progression and safety with continued lecanemab treatment in early Alzheimer’s disease.

Selected Additional Oral and Poster Presentations
Additional oral and poster presentations at CTAD highlight Biogen’s ongoing efforts to advance Alzheimer’s disease diagnosis, treatment and care, including real-world experience with lecanemab, approaches to patient identification and testing, treatment outcomes, and analyses modeling the potential broader impact of slowing disease progression. For a complete list of presentations, please refer to the CTAD scientific program.

• Lecanemab Treatment in Real-World Settings Across Multiple Countries: A Meta-Analysis on ARIA Rates and Safety Profiles in Clinical Practice
  Tuesday, November 17, 2:05–2:20 PM EST
• Lecanemab Treatment and α-Synuclein Co-Pathology in the Clarity AD CSF Substudy
  Thursday, November 19, 1:35–1:50 PM EST
• US Real-World Patterns of Amyloid Testing and Anti-Amyloid Therapy Initiation in Alzheimer’s Disease (AD) and Mild Cognitive Impairment (MCI)
  Poster Session
• Baseline Radiologic Predictors of ARIA-E and ARIA-H: A Quantitative AI-Supported MRI Analysis of a US Real-World Cohort
  Poster Session
• A Prospective, Observational, Fully Decentralized Global Study to Identify Individuals for Alzheimer’s Disease Clinical Trials Using Digital Cognitive Assessments and Blood-Based Biomarkers
  Poster Session

About diranersen (BIIB080)
Diranersen (BIIB080) is an investigational antisense oligonucleotide (ASO) therapy designed to target microtubule-associated protein tau (MAPT) mRNA to reduce the production of tau protein. Abnormal accumulation of tau in the brain is a hallmark of Alzheimer’s disease associated with neurodegeneration and cognitive decline.

Diranersen is being investigated as a potential treatment for early Alzheimer’s disease. In 2025, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to diranersen for the treatment of Alzheimer’s disease. In December 2019, Biogen exercised a license option with Ionis Pharmaceuticals and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize diranersen. Diranersen was discovered by Ionis.

About the CELIA Study
CELIA is a global Phase 2 randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and tolerability of diranersen in individuals with early Alzheimer’s disease. The study enrolled 416 participants with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease dementia. All participants enrolled in CELIA had not previously received anti-amyloid therapy.

The study evaluated three doses of diranersen administered intrathecally over an 18-month placebo-controlled treatment period: 60 mg every six months, 115 mg every six months, and 115 mg every three months.

The primary endpoint of CELIA was assessment of dose response for change from baseline on the Clinical Dementia Rating–Sum of Boxes (CDR-SB) at Week 76. Secondary and exploratory endpoints included additional clinical, biomarker and imaging measures, including cerebrospinal fluid tau biomarkers and tau positron emission tomography (PET). Additional information on the CELIA study design is available in the ClinicalTrials.gov listing for the CELIA study.

An ongoing long-term extension (LTE) study is continuing to evaluate the long-term safety, tolerability and durability of diranersen in early Alzheimer’s disease.

About lecanemab (brand name: LEQEMBI^®)
Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).

Lecanemab has been approved in 53 countries and regions including Japan, the United States, China, Europe, South Korea, Taiwan, and Saudi Arabia, and is under regulatory review in 6 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks was approved in 9 countries including the U.S., China, the UK, and others, and applications have been filed in 11 countries and regions. The U.S. FDA approved Eisai’s Biologics License Application (BLA) for subcutaneous maintenance dosing (360 mg) with LEQEMBI IQLIK in August 2025. For subcutaneous initiation treatment (500 mg), approval was obtained in the U.S. in July 2026 and China in September 2026, and applications are under review in 2 countries.

Eisai and Biogen have been collaborating on the joint development and commercialization of Alzheimer’s disease treatments since 2014. Eisai serves as the lead of LEQEMBI development and regulatory submissions globally, with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.

About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.

We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media – Facebook, LinkedIn, X, YouTube.

Biogen Safe Harbor 
This news release contains forward-looking statements, including, among others, relating to: the potential benefits, efficacy and safety of diranersen (BIIB080) and lecanemab (LEQEMBI); the potential to advance care and improve outcomes for, and address unmet needs of, patients with Alzheimer’s disease; potential regulatory discussions, submissions, decisions and approvals and the timing thereof; the anticipated benefits, risks and potential of our collaboration arrangements; the potential of our commercial business and pipeline programs, including Biogen’s research programs for Alzheimer’s disease; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would” or the negative of these words or other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements.

These forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to differ materially from those stated or implied in this document, including, among others, uncertainty of our long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans, prospects and timing of actions relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product competition in the biopharmaceutical and healthcare industry, as well as any other markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways; our ability to effectively implement our corporate strategy; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; the drivers for growing our business, including our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks related to commercialization of biosimilars, which is subject to such risks related to our reliance on third-parties, intellectual property, competitive and market challenges and regulatory compliance; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; and the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in reports we have filed with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov.

These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in our subsequent reports on Form 10-Q. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.

Digital Media Disclosure
From time to time we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-) and the Biogen X account (https://x.com/biogen) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor our investor relations website and this social media channel in addition to our press releases, SEC filings, public conference calls and webcasts, as the information posted on them could be material to investors.

MEDIA CONTACT: Madeleine Shin + 1 781 464 3260 public.affairs@biogen.com

INVESTOR CONTACT: Tim Power +1 781 464 2442 IR@biogen.com

DEMIRE Deutsche Mittelstand Real Estate AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements

29. Oct 2026 / 11:58 CET/CEST, transmitted by GlobeNewswire.

The issuer is solely responsible for the content of this announcement.

---

DEMIRE Deutsche Mittelstand Real Estate AG hereby announces that the following financial reports shall be disclosed:

Report type: Quarterly report and quarterly/interim statement

Date of disclosure: 05.11.2026

• Language: German
  Address: https://www.demire.ag/publikationen/
• Language: English
  Address: https://www.demire.ag/en/publications/

End of message

---

GlobeNewsWire Distribution Services include regulatory announcements, financial/corporate news and press releases.

Archive at www.globenewswire.com

---